CORDIS
EU research results

CORDIS

English EN
Neuropathic pain: biomarkers and druggable targets within the endogenous analgesia system

Neuropathic pain: biomarkers and druggable targets within the endogenous analgesia system

Objective

Neuropathic pain has a high incidence in Europe and often affects the patient’s emotional balance and quality of life. Recent meta-analyses have shown that conventional analgesic drugs are not sufficiently effective in these patients and are limited by serious side effects. The search for new analgesics is extremely difficult despite identification of several new potential targets and enormous investment by the pharmaceutical industry. Important reasons for this failure are the poor predictive validity of currently available animal models of chronic pain, that do not simulate multidimensional clinical pain, and the high inter-individual variability of neuropathic pain manifestations and treatment responses. We will overcome these obstacles by an interdisciplinary collaboration between basic science groups, clinicians and leading private companies. This consortium will validate new animal models to evaluate the electrophysiological, behavioural, emotional and cognitive manifestations of neuropathic pain and the effectiveness of novel compounds. The use of these models in combination with other behavioural paradigms and new conditional knockout mouse lines for specific components of the endogenous opioid and cannabinoid system will permit the identification of novel druggable targets and biomarkers for neuropathic pain. Novel analgesic compounds acting on these endogenous systems developed by the private companies of the consortium will be tested in these new paradigms. Clinical studies will identify novel biomarkers for neuropathic pain using powerful genetics approaches and investigate treatment effectiveness with a translational focus based on cross validation of the findings in animals and humans.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSIDAD POMPEU FABRA

Address

Placa De La Merce, 10-12
08002 Barcelona

Spain

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 928 000

Administrative Contact

Eva Martin (Ms.)

Participants (10)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITY COLLEGE LONDON

United Kingdom

EU Contribution

€ 545 040

GW PHARMA LIMITED

United Kingdom

EU Contribution

€ 454 999,89

ESTEVE PHARMACEUTICALS, SA

Spain

EU Contribution

€ 206 000,03

CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE

France

EU Contribution

€ 500 800

UNIVERSITAETSKLINIKUM BONN

Germany

EU Contribution

€ 499 800

INSTYTUT FARMAKOLOGII POLSKIEJ AKADEMII NAUK

Poland

EU Contribution

€ 455 000

ISLENSK ERFDAGREINING EHF

Iceland

EU Contribution

€ 846 937

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

Germany

EU Contribution

€ 653 400,04

HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ

Finland

EU Contribution

€ 500 600,04

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 402 000

Project information

Grant agreement ID: 602891

Status

Closed project

  • Start date

    1 January 2014

  • End date

    31 December 2018

Funded under:

FP7-HEALTH

  • Overall budget:

    € 8 540 388,46

  • EU contribution

    € 5 992 577

Coordinated by:

UNIVERSIDAD POMPEU FABRA

Spain